First reported by KELO-AM
GSK’s Jemperli meets main goal in mid-stage rectal cancer trial
GSK Achieves Promising Results in Rectal Cancer Trial with Jemperli
Related Stocks: GSK
Read the full article3d agoen
You might also wanna read
GSK’s Jemperli meets main goal in mid-stage rectal cancer trial
July 13 (Reuters) - GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rat
KELO-AM·3d ago
GSK to file Jemperli for rectal cancer after phase 3 readout
GSK to file Jemperli for rectal cancer after phase 3 readout Phil.Taylor Mon, 13/07/2026 - 11:42
pharmaphorum·3d ago
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
GSK·3d ago
GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
Biotech firm is developing small molecules for lung cancers
cen.acs.org·1mo agoGSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
GSK·6d ago
NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer
Conditions : Colon Cancer Metastatic Interventions : Drug: Retifanlimab; Drug: Zanzalintinib Sponsors : Northwell Health Not yet recruiting
clinicaltrials.gov·16d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.